Alector Inc · Q2 2024 earnings

Briefing

Alector's progress in clinical trials and strong financial position were highlighted.

Alector reported a net loss of $38.7 million for Q2 2024, with collaboration revenue of $15.1 million. The company's cash, cash equivalents, and investments totaled $503.3 million, expected to fund operations through 2026. Key clinical trials for AL002 and latozinemab are progressing, with potential data readouts and regulatory interactions anticipated.

• INVOKE-2 Phase 2 clinical trial data for AL002 in early Alzheimer’s disease is expected in Q4 2024.
• The pivotal INFRONT-3 Phase 3 trial of latozinemab continues to progress well, supported by FDA interaction post Breakthrough Therapy Designation.
• Alector's cash, cash equivalents, and investments totaled $503.3 million, providing runway through 2026.
• Alector is advancing its Alector Brain Carrier (ABC) technology for delivering drugs into the CNS.

Headline financials

Revenue & EPS history

Alector anticipates collaboration revenue between $60 million and $70 million. Total research and development expenses are expected to be between $210 million and $220 million, and total general and administrative expenses are projected to be between $60 million and $70 million.